Pfizer pays $15m advance on PhIII milestone for sickle cell drug
This article was originally published in Scrip
Executive Summary
Relief for GlycoMimetics as Pfizer pays up $15m of the $35m milestone payment which was due on the start of a Phase III of the drug candidate rivipansel (GMI-1070). Pfizer however has yet to disclose when the trial of the sickle cell disease treatment will actually begin.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.